Jan M Keppel Hesselink
Director
Institute for Neuropathic Pain
Netherlands
Biography
Jan M. Keppel Hesselink, MD, MSc, PhD received his MSc in biology (cum laude) at the university of Utrecht; his degree in medicine, MD in Utrecht, his PhD (thesis on Parkinson's disease) at the university of Nijmegen, the Netherlands. Professor of molecular pharmacology, University Witten/Herdecke, Germany. Currently working as: 1. Consultant: due diligence for Investment Management in Biotech and Pharmaceuticals and * R&D advice within the field of drug development. 2. Pain physician and director at the Institute for Neuropathic Pain: www.neuropathy.nl In 1996 he was appointed professor of molecular pharmacology at the university of Witten/Herdecke (Germany). In the same period, he was elected as Fellow of the Pharmaceutical Faculty in Medicine (FFPM) in the UK. He worked several years at Bayer AG in Germany as VP CNS and business head CNS worldwide. He became director at Licentec and advisor R&D to the Dutch Royal Academy of Science (KNAW) and institutes, such as the Hubrecht Institute, where he assisted spin-outs. He was CEO of the Academic Medical Centre Amsterdam’s (AMC) institute for antiviral therapy: IATEC. In 2009 he started the Institute for Neuropathic Pain, since then 8 different novel topical analgesic creams have been developed as compounded creams. He holds 2 recent patents on the topical use of phenytoin for the treatment of neuropathic pain. He wrote a number of books in the field of neurology and many book chapters, and published extensively in the fields of neurology, neuropathy, pharmacology, CNS, pharmaceutical medicine, drug development, pharmacotherapy, pain, analgesia, transdermal and topical treatments. His current focus is on drug development and drug repurposing/repositioning. He is on the editorial board of a number of medical journals, among those the Journal of Pain Research and the Journal of Clinical Trials & Patenting.
Research Interest
Research and Development bottlenecks in pharmaceutical medicine and Biotech, Autacoid Medicine and on new innovative topical analgesic formulations, among which phenytoin, ketamine and baclofen.